Biotech Values

[mcbio]

Right and I expect the results of those studies to be very good. Remember that VRUS initiated these studies and it's my opinion that GILD would prefer to develop in-house regardless of how exciting these results may be.

I am hopeful that any positive results from the GS-7977/TMC435 combo trial will be enough to get Medivir shares moving, irrespective of GILD's ultimate plans, which is why I'm long Medivir. We shall see.